Making the Case: Leukomed® Sorbact®

Share this article

Making the Case: Leukomed® Sorbact®

Supported by BSN Medical
11 January 2015

Surgical site infection (SSI) is the third most common type of healthcare-associated infection (HCAI), accounting for about 16% of all HCAIs; they are estimated to affect 6.4% of patients in healthcare systems in England (Health Protection Agency, 2011).

Free for all healthcare professionals

Sign up to the Wounds Group journals

By clicking ‘Subscribe’, you are agreeing that the Wounds Group are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our privacy policy.

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.

I am not a healthcare professional.